Clinical efficacy of neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP) after operation in advanced ovarian cancer
-
摘要:
目的 探讨新辅助化疗联合肿瘤细胞减灭术及术后腹腔热灌注治疗晚期卵巢癌的临床疗效。 方法 分析郑州人民医院从2009年4月至2012年7月收治的60例晚期卵巢癌的患者，分为两组，研究组患者术前采取新辅助化疗联合肿瘤细胞减灭术及术后腹腔热灌注辅助化疗2次（顺铂80 mg），术后给予TC/TP方案化疗，对照组采取常规肿瘤细胞减灭术+术后TC/TP方案化疗，比较两组患者在手术时间、出血量、腹水量、术后化疗疗程、疗效、复发与死亡、生存率等数据的差异。 结果 研究组患者在术中的各项疗效指标优于对照组，且有统计学显著性差异（P < 0.05），临床治疗有效率高于对照组。 结论 在临床上对于晚期卵巢癌患者采取术前新辅助化疗联合肿瘤细胞减灭术术后腹腔热灌注辅助化疗，对于患者的疗效较常规的方法有较大的提高，值得在临床上进行推广。 Abstract:Objective We aimed to investigate the clinical efficacy of neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP) after the operation of patients with advanced ovarian cancer. Methods Analysis of 60 patients with advanced ovarian cancer was performed at the Zhengzhou People's Hospital from April 2009 to July 2012. The patients were divided into two groups, namely, the research and control groups. The research group was treated with neoadjuvant chemotherapy combined with cytoreductive surgery and IHCP twice (cisplatin at 80 mg), and subsequently, with chemotherapy (TC/TP). The control group underwent primary cytoreductive surgery and chemotherapy (TC/TP). We compared the differences between the two groups in terms of the following parameters: operation time, bleeding volume, volume of ascites, and postoperative chemotherapy. Results The treatments in the research group were more efficient than those performed on the control group in terms of all the intraoperative indicators, and the difference between the two groups was statistically significant (P < 0.05). Conclusion Compared with conventional methods, the neoadjuvant chemotherapy combined with cytoreductive surgery and IHCP after operation was more effective for patients with advanced ovarian cancer. Thus, neoadjuvant chemotherapy combined with cytoreductive surgery and IHCP after operation can be applied in clinical settings. -
表 1 两组患者的术后恢复、并发症及手术切口愈合比较
Table 1. Comparison of the postoperative recovery between the two groups of patients
-
[1] Cao ZY. Chinese Obstetrics and gynecology(2)[M]. Second edition. Beijing: People's Medical Publishing House, 2005:2153- 2271.曹泽毅, 主编.中华妇产科学(下册)[M].第2版.北京:人民卫生出版社, 2005: 2153-2271. [2] Krasner C, Duska L. Management of women with newly diag nosed ovarian cancer[J]. Semin Oncol, 2009, 36(2):91-103. https://www.nice.org.uk/Guidance/CG122 [3] 谢幸, 苟文丽, 主编.妇产科学[M].第8版.北京:人民卫生出版社, 2008:313.Xie X, Gou WI. Obstetrics and Gynecology[M]. Eighth Edition. Beijing:People's medical publishing house. [4] 刘璐婷, 徐世强, 张国楠.新辅助化疗在晚期卵巢上皮性癌综合治疗中的临床研究[J].中国实用妇科与产科杂志, 2013, 3(4):264-268.Liu LT, Xu SCI, Zhang GN. Clinical research of neoadjuvant che motherapy on advanced epithelial ovarian cancer[J]. Chinese Jour nal of Practical Gynecology and Obstetrics. 2013, 3(4):264-268. [5] 林芳, 彭一, 杜驰, 等.晚期卵巢癌新辅助化疗的疗效分析[J].现代预防医学, 2011, 38(13): 2637-2639. doi: 10.3969/j.issn.1671-8194.2011.35.022Lin F, Peng Y, Du C, et al. Aclinical study on advanced ovarian cancer by neoadjuvant chemotherapy[J]. Modern of Preventive Medicine. 2011. 38(13):2637-2639. doi: 10.3969/j.issn.1671-8194.2011.35.022 [6] Colevas AD, SETSER a. The NCI common terminology criteria for adverse events(CTCAE)V 3.0 is the new standard for oncology clinical trisas[J]. J Clin Oncol, 2004, 22(14S):S6098. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf [7] 连利娟, 林巧稚, 主编.妇科肿瘤学[M].北京:人民卫生出版社, 2008:580-594.Lian L, Lin Q. Gynecologic Oncology[M]. Beijing:People's medical publishing house. 2008:580-594. [8] Glasgow MA, Yu H, Rutherford TJ, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovrain cancer (FIGO Stage Ⅲ and Ⅳ)[J]. J Surg On col, 2013, 107(2):195-200. [9] De Vita F, Orditura M, Matano E, et al. A phase Ⅱ stuady of bi weekly oxalipalatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer pa tients[J]. Br J Cancer, 2005, 92(9):1644-1649. [10] Vander Zee J. Heating the patient: a promising approach[J]. Ann Oncol, 2002, 13(8):1173-1184. doi: 10.1093/annonc/mdf280 [11] Marmor JB. Interactions of hypertherapr in animals[J]. Cancer Res, 1979, 39(6pt2):2269-2276. https://www.ncbi.nlm.nih.gov/pubmed/24001757 [12] 刘凤珍, 刘晓明, 刘锋, 等.新型热灌注机及装置在21例卵巢癌术中腹腔热灌注化疗的应用[J].实用妇产科杂志, 2012, 28(10):834-837. doi: 10.3969/j.issn.1003-6946.2012.10.014Liu FZ, Liu XM, Liu F, et al, Application of New Type Machines and Devices of Intraperitoneal Hyperthermic Perfusion Chemother apy in Ovarian Cancer Surgery[J]. Journal of Practical Obstetrics and Gynecology, 2012, 28(10):834-837. doi: 10.3969/j.issn.1003-6946.2012.10.014 [13] 简萍, 李斌, 衣倩红.腹腔热灌注化疗治疗卵巢恶性肿瘤的临床观察[J].中国妇幼保健, 2013, 28(12):1974-1977. doi: 10.3969/j.issn.1009-4393.2016.29.021Jan P, Li B, Yi QH. Clinical observation on intraperitoneal hyper thermic perfusion chemotherapy in the treatment of ovarian cancer [J]. Chinese Maternal and Child Health, 2013, 28(12):1974-1977. doi: 10.3969/j.issn.1009-4393.2016.29.021 [14] 陈非, 郭黔, 罗舒, 等.腹腔热灌注联合化疗治疗恶性腹腔积液的疗效观察[J].重庆医学, 2011, 12(40):3465-3466. doi: 10.3969/j.issn.1672-3511.2013.02.032Chen F, Guo Q, Luo S, et al. Observation on curative of intraperto neal chemohyperhermia combined with systyemic chemother in treatment of malignant ascites[J]. Chongqing Medical, 2011, 12(40): 3465-3466.[ doi: 10.3969/j.issn.1672-3511.2013.02.032 [15] 孙玉芬.腹腔热灌注联合全身化疗治疗卵巢癌恶性腹腔积液的近期疗效[J].中国肿瘤临床与康复, 2014, 4(20): 369-370.Sun YF. Clinical effect of intraperitoneal hyperthermic perfusion combined with systemic chemotherapy in ovarian cancer malignant ascites[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2014, 4(20):369-370. -
点击查看大图
表(1)
计量
- 文章访问数: 36
- HTML全文浏览量: 6
- PDF下载量: 2
- 被引次数: 0
下载:
